Global Rheumatic Disorders Drugs Market Grow at (CAGR) of 4.46% to $80.04 billion in 2024

Global Rheumatic Disorders Drugs Market to 2024 research report covers key diseases of rheumatic disorders, market size, therapy area overview, etiology, Epidemiology Patterns and Forecasts - Prevalence and Patient Segmentation and key marketed products.

Pune, India - February 12, 2019 /MarketersMedia/ —

Global Rheumatic Disorders Drugs Market to 2024 - Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent Expiry research report added to ReportsnReports online database.
The rheumatic disorder therapy area is multi-disciplinary in nature and encompasses conditions that affect joints, connective tissue, ligaments, tendons, cartilage, bone and muscle and which are characterized by chronic pain and a consequent reduction in function and motion. The majority of rheumatic disorders are treated using largely genericized pain management drugs, and there are no cures for any of the key indications, leaving a large unmet need for better disease-modifying drugs to be developed.

Get Discount on Rheumatic Disorders Drugs Market Research Report at https://www.reportsnreports.com/contacts/discount.aspx?name=1854866

This report covers all rheumatic disorders, but there is a particular focus on five key diseases, rheumatoid arthritis, osteoarthritis, osteoporosis, systemic lupus erythematosus and psoriatic arthritis, as these conditions have the largest pipelines within the therapy area.

The market size for rheumatic disorder therapeutics was $58.97 billion in 2017 and is expected to grow at a compound annual growth rate (CAGR) of 4.46% to $80.04 billion in 2024.

Scope

- How is the rheumatic disorders market landscape expected to change?
- Which drugs will face patent expiry, biosimilar competition and decreasing revenue over the forecast period?
- Overall, there are 1,069 products in the rheumatic disorder pipeline, how does the composition of the pipeline compare with that of the existing market?
- Which molecular targets are most prominent within the pipeline and how do the key indications differ in terms of their pipeline composition?
- The market size for rheumatic disorder therapeutics is expected to grow, from $58.97 billion in 2017 to $80.04 billion in 2024, at a CAGR of 4.46%. Which products will contribute to market growth most, and which will achieve blockbuster status?
- What types of companies are involved in the rheumatic disorder therapy area?
- Will the current market leaders retain their dominance over the forecast period?
- How many strategic consolidations have been completed in the past decade and which types of assets attract the largest deal values?

Reasons to Buy:
This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis for the five key indications
- Understand how the patent expiries of the key, blockbuster anti-TNF drugs will affect the Rheumatic Disorder Drug Market
- Identify trends and developments in the rheumatic disorder pipeline and consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates
- Identify which two drug classes will see particularly strong market growth over the forecast period
- See how or if the companies marketing anti-TNF drugs facing patent expiry will be able to offset biosimilar erosion
- Identify commercial opportunities in the rheumatic disorder deal landscape by analyzing trends in licensing and co-development deals

Direct Purchase of Rheumatic Disorders Drugs Market Research Report at https://www.reportsnreports.com/purchase.aspx?name=1854866

Table of Contents:
1. Introduction
2. Key Marketed Products
3. Pipeline Landscape Assessment
4. Multi-scenario Market Forecast to 2024
5. Company Analysis and Positioning
6. Strategic Consolidations
7. Appendix

Contact Info:
Name: Vishal Kalra
Email: Send Email
Organization: ReportsnReports
Website: https://www.reportsnreports.com/reports/1854866-global-rheumatic-disorders-drugs-market-to-2024-increased-uptake-of-il-inhibitors-and-jak-inhibitors-to-drive-growth-as-tnf-inhibitors-face-patent-expiry.html

Source URL: https://marketersmedia.com/global-rheumatic-disorders-drugs-market-grow-at-cagr-of-446-to-8004-billion-in-2024/481750

Source: MarketersMedia

Release ID: 481750

More News From Entertainment - The World Insiders

Biden hires strategist Symone Sanders, adds diversity to bid

Apr 25, 2019

WASHINGTON — Joe Biden has hired Symone Sanders, a prominent African American political strategist, as a senior adviser to his newly launched presidential campaign. The move adds a younger, diverse voice to Biden's cadre of top advisers, which has been dominated by older white men. It suggests Biden is seeking to broaden his appeal to a new generation of Democrats. Sanders, 29, rose to prominence during the 2016 campaign as press secretary for Vermont Sen. Bernie Sanders. She then became a high-profile political analyst on CNN and is likely to be a forceful Biden defender on television. Democratic strategist and...

Sanders holds 1st press briefing since Feb. 28, but for kids

Apr 25, 2019

WASHINGTON — White House press secretary Sarah Sanders held her first briefing in more than a month Thursday, but the questions didn't come from working journalists. Sanders made herself available for what the White House said was a "kids-only press briefing" held for children participating in "Take Our Daughters and Sons to Work Day." Journalists who cover President Donald Trump and the White House on a daily basis have been waiting for a similar opportunity since Feb. 28, the last time Sanders held a briefing. The White House announced that the briefing would be off the record and not for...

Wet forecast puts damper on 50th Jazz Fest opening day

Apr 25, 2019

NEW ORLEANS — A wet forecast put a damper on opening day of the 50th New Orleans Jazz and Heritage Festival. The National Weather Service said there was an 80% chance of rain Thursday and some storms might be severe. More than 70 acts including Earth, Wind and Fire and Alanis Morissette are scheduled Thursday, along with scores of food and arts and crafts vendors. The festival generally goes on rain or shine, though storms canceled one Friday in 2004. In 2016, storms ended the next-to-last day before Stevie Wonder and other headliners could start. The following day, some closers...

Sale of tickets for Woodstock 50 delayed for now

Apr 25, 2019

NEW YORK — The much-anticipated sale of tickets for this summer's Woodstock 50 anniversary concerts has been put on hold for now. Tickets for the three-day festival on Aug. 16-18 were supposed to be available on Monday. The festival released a statement Thursday, saying: "Woodstock 50 has delayed its on sale while we refine logistical plans." The statement adds, "Ticket on sale information will be available through Woodstock.com in the coming days." Jay-Z, Dead & Company and the Killers were announced as headliners of Woodstock 50, commemorating the groundbreaking Woodstock festival. The festival is set to take place in Watkins...

New Prince album featuring unreleased demos out in June

Apr 25, 2019

NEW YORK — A new Prince album featuring his versions of songs he wrote for other artists will be released in June. The 15-track "Originals" will include "Nothing Compares 2 U," the No. 1 hit for Sinéad O'Connor; "The Glamorous Life," Sheila E.'s signature song and Top 10 pop hit; and Kenny Rogers' "You're My Love," which Prince wrote under the name Joey Coco in 1986. The album will be available on Jay-Z's Tidal streaming platform exclusively for two weeks starting June 7, which would have been his 61st birthday; it will be widely available on June 21, including Spotify...

About Us

The World Insiders brings you exclusive coverage from across the globe in a timely, easy to consume format sourced directly from our regional media partners.

Contact us: sales[at]theworldinsiders.com

Subscribe Now!